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Background: Microscopic polyangiitis (MPA) is a necrotizing vasculitis that affects
predominantly small-sized vessels in many organ systems. The disease generally
causes glomerulonephritis, pulmonary damage, arthritis, and neuropathy. An exclusive
involvement of both central nervous system (CNS) and peripheral nervous system (PNS)
is extremely rare.
Case Presentation: A 62-year-old woman was admitted to our hospital with a
3 months history of right foot drop, recently complicated by intense myalgia, arthralgia,
and allodynia to tactile, vibratory, and pressure stimuli. Since blood tests revealed
elevated inflammatory indexes, we suspected either infectious or immune-mediated
disorders. Chest radiograph, blood culture series, and echocardiogram revealed normal
findings, while urinalysis showed a bacterial infection that was successfully treated. The
neurophysiological findings were compatible with multiple mononeuritis, and a brain
MRI evidenced ischemic lesions of both basal ganglia and thalamus. A wide-spectrum
autoantibody assay revealed the presence of high-titer perinuclear anti-neutrophil
cytoplasmic antibodies specific for myeloperoxidase (MPO-ANCA). According to these
findings, the diagnosis of MPA was made, and the patient was successfully treated with
intravenous (IV) methylprednisolone, followed by two doses of rituximab.
Conclusions:An assessment of both CNS and PNS should be included in the diagnostic
evaluation of MPA. The involvement of the PNS may raise the risk of a relapsing course
and treatment failure, therefore it should be considered in the choice of induction and
maintenance therapy.
Keywords: microscopic polyangiitis, vasculitis, central pain, peripheral neuropathy, allodynia, foot drop,
anti-neutrophil cytoplasmic antibodies specific for myeloperoxidase (MPO-ANCA)
BACKGROUND
Microscopic polyangiitis (MPA) is a necrotizing vasculitis that affects small- and some
medium-sized vessels, often associated with perinuclear anti-neutrophil cytoplasmic antibodies
specific for myeloperoxidase (MPO-ANCA) (1).
In most cases, MPA presents as rapidly progressive glomerulonephritis, pulmonary capillaritis,
and general symptoms, including fatigue, fever, anorexia, muscle, and joint pain. The involvement
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of the peripheral nervous system (PNS) is also possible
and not infrequent: distal symmetrical polyneuropathy and
mononeuritis multiplex occur in more than a third of cases
(2). Instead, central nervous system (CNS) involvement is less
frequently described and generally consists of intracerebral or
subarachnoid hemorrhage (3), pachymeningitis (4), and ischemic
strokes (5).
Here we report a case of MPA patient who presented
with an exclusive involvement of the nervous system, both
peripherical and central. The patient provided her written
informed consent for the publication of this case report and any
accompanying images.
CASE PRESENTATION
A 62-year-old woman was admitted to our hospital with a
3-month history of right foot drop, generalized weakness, apathy,
and weight loss (4 kg), recently complicated by the development
of diffuse pain with intense myalgia and arthralgia, unresponsive
to analgesics.
Patient’s history revealed a previous diagnosis of fibromyalgia
and positivity for rheumatoid factor without anti-cyclic
citrullinated peptide antibodies. Despite periodic chronic
widespread pains, the patient has always been in good health.
Preliminary blood tests showed high values of C-reactive
protein (CRP; 20.24 mg/dl; normal <0.5 mg/dl) and elevated
white blood cell count (WBC; 17.350/mm3).
A neurologic examination confirmed the distal motor
deficit of the right leg with muscle strength evaluated as 1/5
in right foot dorsiflexors and as 2/5 in plantar flexors on
the Medical Research Council (MRC) scale. Hypoesthesia
to pinprick and touch in a sock and glove distribution was
detected. Deep tendon reflexes were present and symmetrical,
except for right ankle reflex, which could not be elicited.
Gait was slightly unsteady and typically stepping because
of the foot drop. The patient showed a severe anxious
state and an abnormal painful reaction to sensory stimuli,
configuring a condition of hyperpathia and allodynia.
Therefore, an analgesic therapy with transdermal fentanyl
was started.
The subacute/acute onset of symptoms and the high level
of inflammatory markers would suggest either infectious
or immune-mediated disorders. Chest radiograph excluded
parenchymal infiltrates or pleural effusions. Blood culture series
were negative. Echocardiogram was within normal limits and
showed no vegetations. The urinalysis demonstrated hematuria
with high levels of bacteria and leukocyte esterase; a subsequent
urine culture confirmed an Escherichia coli infection that
was successfully treated according to the antibiogram. Despite
this therapy, the inflammatory markers remained significantly
elevated [CRP 20.12 mg/dl; WBC 15.300/mm2; erythrocyte
sedimentation rate (ESR) 89mm] and a minimal hematuria
persisted in the 2 days following the end of antibiotic therapy.
Of note, a progressive bilateral wrist drop appeared 3 days
after hospital admission.
Electromyography (EMG) revealed the absence of the
sensory nerve action potentials (SNAPs) in the left median
nerve and a reduction of conduction speed in the right
median nerve. The amplitude of the compound muscle
action potential (CMAP) was reduced in the left median
nerve and, more markedly, in the right peroneal nerve,
with preserved conduction velocity. Both CMAP amplitude
and conduction velocity were reduced in the right ulnar
nerve distal to the elbow. Needle EMG revealed active
denervation in the right tibialis anterior muscles, right medial
twin, short head of the right biceps femoris muscle, right
abductor digiti minimi, and left common extensor of the
fingers. Those findings were compatible with a marked
sensory–motor axonal suffering in active phase, with a multi-
neuropathic distribution.
Despite opioid analgesic therapy, the patient continued to
suffer from widespread pain, with marked allodynia to tactile,
vibratory, and pressure stimuli. Assuming a central origin of the
pain, brainMRI was performed, revealing hyperintense lesions in
the left thalamus, right caudate, and lenticular nuclei on T2/fluid-
attenuated inversion recovery (FLAIR) images (Figures 1A,B),
characterized by restricted diffusion (Figure 1C), without edema
nor contrast enhancement.
The cerebrospinal fluid (CSF) composition was normal;
real-time PCR assay for pathogens associated with CNS
infection [herpes simplex virus (HSV)1, HSV2, varicella zoster
virus (VZV), human herpesvirus (HHV)6, cytomegalovirus
(CMV), enterovirus, parechovirus, Neisseria meningitidis,
Haemophilus influenzae, Streptococcus pneumoniae, E. coli,
Listeria monocytogenes, and Cryptococcus neoformans]
was negative. Oligoclonal bands were absent in serum
and CSF.
Serology revealed the presence of high-titer MPO-
ANCA (278.30 UI/ml; reference <5.97 UI/ml). All the
other autoantibodies tested [c-ANCA, anti-dsDNA, lupus
anticoagulant, anti-phospholipid, autoantibodies to thyroid
peroxidase (anti-TPO), autoantibodies to thyroglobulin (anti-
Tg), autoantibodies to mitochondrial antigen (AMA), liver
kidney microsome (LKM), anti-smooth muscle antibodies
(ASMA), extractable nuclear antigen (ENA), anti-cyclic
citrullinated peptide antibody (anti-CCP), anti-Scl70,
anti-pmScl, anti-PL7, anti-Jo1, anti-signal recognition
particle (anti-SRP)-S4, anti-Mi2, anti-Ku, anti-PL12]
resulted negative.
MPO-ANCAs are autoantibodies associated to different
types of small vessel vasculitis, like MPA, and eosinophilic
granulomatosis with polyangiitis.
Considering the clinical presentation and the absence of
eosinophilia, the patient was diagnosed with MPA.
MPA usually involves small vessels, but in order
to exclude the involvement of medium vessels, we
performed a magnetic resonance angiography of
extracranial carotid arteries and intracranial vessels, which
resulted negative.
In order to investigate the possibility of multi-organ
involvement, additional testing was conducted. Pulmonary
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FIGURE 1 | MRI of the brain. (A) T2/fluid-attenuated inversion recovery (FLAIR) coronal view shows hyperintensity in the right caudate, internal capsule, and putamen.
(B) T2/FLAIR axial view shows additional lesions involving left thalamus and lenticular nuclei. (C) Diffusion-weighted imaging axial view shows three lesions with
restricted diffusion. Arrows indicate CNS lesions.
FIGURE 2 | MRI of the brain after 3 months of follow-up. T2/fluid-attenuated inversion recovery (FLAIR) coronal (A) and axial (B) views show size reduction of the
pre-existing lesions in the basal ganglia, thalamus, and internal capsule. (C) Diffusion-weighted imaging axial view showing no signal alteration. Arrows indicate CNS
lesions.
CT scan was unremarkable; urinary sediment examination,
creatinine, and BUN were normal.
The patient was started on steroidal therapy with intravenous
(IV) methylprednisolone 1 g for 5 days, followed by oral
tapering with prednisone. After this treatment, peripheral
sensitivity improved, inflammatory markers lowered (CRP
2.99 mg/dl; WBC 11.620/mm2), and anti-MPO antibodies
started to decrease (209.2 UI/ml). However, foot and wrist
drop minimally improved. Therefore, we chose to complete
the induction therapy with a single dose of rituximab (1 g),
followed by a second dose after 2 weeks, which led to
a significant clinical improvement of hands motor deficit
and also to a further decrease in the antibodies level
(49.4 UI/ml).
After discharge from the hospital, the patient started
neurorehabilitation and has since undergone neurophysiological,
neuroradiological, and immuno-rheumatologic follow-up.
In the following 6 months, anti-MPO antibodies continued
to decrease, the foot drop progressively resolved, and the patient
returned to be completely asymptomatic.
A brainMRI performed 3months after admission showed size
reduction of the pre-existing lesions without further alterations
in signal intensity nor restriction in the diffusion-weighted
sequences (Figure 2).
DISCUSSION AND CONCLUSIONS
Our patient presented an almost exclusive involvement of the
nervous system: she developed a typical multiple mononeuritis,
while the ischemic lesions of both basal ganglia and thalamus
witnessed the lenticulostriate arteries involvement. The severe
allodynia may have multiple causes: CNS lesions may account
for a thalamic pain syndrome or central post-stroke pain (6), as
well as vasculitis-associated neuropathy, and myalgia may also
contribute to the hyperpathic syndrome.
Having excluded other diseases, the diagnosis of MPA was
achieved because of MPO positivity and compatible clinical
features using the EuropeanMedicines Agency (EMA) algorithm
(7). Despite the major and almost isolated involvement of
the nervous system, a minimal renal inflammation cannot
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be completely ruled out since the patient suffered from a
slight hematuria.
The 2012 Revised International Chapel Hill criteria (8)
could not be completely fulfilled, standing the absence of lung
involvement, evident renal vasculitis, and histology proving
necrotizing vasculitis.
Indeed, the classification of ANCA-associated small-vessel
vasculitis remains complex in actual clinical practice. As a matter
of fact, nearly 50% of patients are classified according to ANCA
specificities without being able to fulfill the current diagnostic
criteria (9).
We decided not to perform a nerve biopsy because the
ANCA+ serology and the treatment response strongly suggested
the diagnosis; besides, considering the segmental nature of the
vasculitis, serial nerve sections should have been performed to
obtain a good sensitivity (10). However, in the absence of such
a significant antibody positivity, a nerve biopsy would have
been recommended.
An isolated involvement of both CNS and PNS is exceptional
in MPA; in a Spanish series with 167 MPA patients, neurological
involvement was detected in 30.5% of patients, of whom
only 5.4% had cerebrovascular accidents (11). Ito et al.
(12) reported a case of ANCA-associated vasculitis causing
bilateral cerebral infarction without renal and respiratory
dysfunction, but in absence of PNS involvement. To our
knowledge, only Sassi et al. (13) described a 48-year-old
man who developed mononeuritis multiplex and massive
cerebral hematoma apparently without any other systemic
damage. Other cases reported in literature describe patients
with hemorrhagic involvement of CNS accompanied by
glomerulonephritis (14–16).
Treatment for MPA consists of IV prednisone in the
acute setting, while cytotoxic drugs (e.g., cyclophosphamide,
azathioprine), are chosen for maintenance therapy (17).
Rituximab is another Food and Drug Administration (FDA)-
approved option in combination with glucocorticoids and
has been shown to be more effective than azathioprine
for maintenance of remission (18). According to literature
evidences, MPA patients with mononeuritis multiplex require
more intensive treatments, since the risk of relapsing course and
treatment failure is higher (19).
In conclusion, the diagnostic evaluation of MPA should
include an assessment of both CNS and PNS, considering their
relatively high frequency of involvement. Patient’s characteristics,
disease severity, and high risk of relapsing course should be
considered in the choice of induction and maintenance therapy.
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